Coya Therapeutics Inc (COYA) Announces Clinical Trial Update
Coya Therapeutics Inc (COYA) provided an update on its clinical development programs.
Clinical Development Highlights:
Collaboration: COYA
🔬 Clinical Development Pipeline (Coya Therapeutics Inc):
Product
Type
Development Stage
Therapeutic Area
Source
CSTI-500
DRUG
Phase PHASE2
Prader-Willi Syndrome
ClinicalTrials.gov
Placebo
DRUG
Phase PHASE2
Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov
COYA 302
DRUG
Phase PHASE2
Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov
IRay
DEVICE
Phase PHASE1
Age-Related Macular Degeneration
ClinicalTrials.gov
iCo-007 Intravitreal Injection
DRUG
Phase PHASE1
Diffuse Diabetic Macular Edema
ClinicalTrials.gov
Lucentis
DRUG
Approved
Retinal Pigment Epithelial Detachment With Vascularization
📋 Coya Therapeutics Inc (COYA) - Clinical Trial Update
Filing Date: 2026-01-20
Accepted: 2026-01-20 08:20:20
Event Type: Clinical Trial Update
Event Details:
🔬 Clinical Development Pipeline (Coya Therapeutics Inc):
💼 Business Developments:
No business developments data available.
Structured Data: